PainReform Ltd. (PRFX)

IL — Healthcare Sector
Peers: GSAC  IMCC  LIXT  MDIA  MTVA  NLSP  UPC  VRPX 

Automate Your Wheel Strategy on PRFX

With Tiblio's Option Bot, you can configure your own wheel strategy including PRFX - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.

Start Your Free Trial Now

Key Metrics & Ratings

  • symbol PRFX
  • Rev/Share 0.0
  • Book/Share 1.24
  • PB 1.0968
  • Debt/Equity 0.0247
  • CurrentRatio 1.8133
  • ROIC -6.899

 

  • MktCap 2737872.0
  • FreeCF/Share -8.5887
  • PFCF -0.2167
  • PE -0.1371
  • Debt/Assets 0.0099
  • DivYield 0
  • ROE -16.8891

 

  • Rating C+
  • Score 2
  • Recommendation Sell
  • P/E Score 1
  • DCF Score 5
  • P/B Score 3
  • D/E Score 2

Recent Analyst Ratings

Type Ticker Analyst Firm Previous Rating Current Rating Previous Price Target Current Price Target Date
No ratings available.

News

PainReform Provides Business Update for the Six Months Ended June 30, 2025
PRFX
Published: October 01, 2025 by: GlobeNewsWire
Sentiment: Neutral

TEL AVIV, Israel, Oct. 01, 2025 (GLOBE NEWSWIRE) -- PainReform Ltd. (Nasdaq: PRFX), a specialty pharmaceutical company focused on the reformulation of established therapeutics and commercialization of AI-driven solar analytics technologies, today provided a business update for the six months ended June 30, 2025.

Read More
image for news PainReform Provides Business Update for the Six Months Ended June 30, 2025
Nvidia enrollment sends this stock soaring 130%
PRFX
Published: August 19, 2025 by: Finbold
Sentiment: Positive

Shares of Israel-based pharmaceutical company PainReform (NASDAQ: PRFX) jumped nearly 130% on Tuesday after its renewable energy arm, DeepSolar, was accepted into the Nvidia (NASDAQ: NVDA) Connect Program.

Read More
image for news Nvidia enrollment sends this stock soaring 130%
Blade Ranger: Consideration from PainReform Transaction Continues to Mature Following Growth in Software Sales
PRFX
Published: May 27, 2025 by: PRNewsWire
Sentiment: Neutral

As a result of increased software sales by the acquirer, and in accordance with the terms of the software business sale agreement, a significant number of zero-exercise-price warrants have matured—Blade Ranger now holds approximately 1 million shares and warrants exercisable at no additional cost TEL AVIV, Israel , May 27, 2025 /PRNewswire/ -- Blade Ranger Ltd. (TASE: BLRN), a company listed on the Tel Aviv Stock Exchange, announced the achievement of a first milestone in the transaction involving the sale of its DeepSolar operations to PainReform (NASDAQ: PRFX).

Read More
image for news Blade Ranger: Consideration from PainReform Transaction Continues to Mature Following Growth in Software Sales
PainReform Completes Strategic Acquisition of DeepSolar, Unlocking New Growth Opportunities in AI-Driven Solar Analytics
PRFX
Published: March 05, 2025 by: GlobeNewsWire
Sentiment: Neutral

Acquisition Positions PainReform as a Potential Leader in High-Growth, High-Margin AI Solar Energy Management While Continuing Its Core Focus on Pharmaceutical Innovation Acquisition Positions PainReform as a Potential Leader in High-Growth, High-Margin AI Solar Energy Management While Continuing Its Core Focus on Pharmaceutical Innovation

Read More
image for news PainReform Completes Strategic Acquisition of DeepSolar, Unlocking New Growth Opportunities in AI-Driven Solar Analytics

About PainReform Ltd. (PRFX)

  • IPO Date 2020-09-01
  • Website https://www.painreform.com
  • Industry Drug Manufacturers - Specialty & Generic
  • CEO Ehud Geller
  • Employees 2

PainReform Ltd., a clinical stage specialty pharmaceutical company, engages in the development of therapeutics that provides an extended period of post-surgical pain relief in Israel. It engages in developing PRF-110, a viscous clear oil-based solution that is instilled directly into the surgical wound to provide localized and extended post-operative analgesia. The company is currently conducting two Phase 3 clinical trials of PRF-110 for the treatment of patients undergoing bunionectomy surgery and hernia repair. PainReform Ltd. was incorporated in 2007 and is based in Tel Aviv, Israel.